EUORBIO SCIENTIFIC: 2022 TURNOVER OF €152.5M 15% CORE BUSINESS GROWTH AT €93M
23 janv. 2023 11h45 HE
|
Eurobio Scientific
2022 TURNOVER OF €152.5M 15% CORE BUSINESS GROWTH AT €93M • Growth of proprietary products reaching 18% of core revenues1• Internationalization of the Group at 25% of core revenues1• Core...
Eurobio Scientific : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
05 janv. 2023 12h00 HE
|
Eurobio Scientific
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE Paris, le 05 janvier 2023 –18h00 Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié...
Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer
22 nov. 2022 11h45 HE
|
Eurobio Scientific
Eurobio Scientific and Acobiom announce the signature of an exclusive commercial agreement for the distribution of a diagnostic test that predicts response to a treatment for pancreatic cancer CE...
Eurobio Scientific et Acobiom annoncent la signature d’un accord commercial pour la distribution exclusive d’un test diagnostique prédictif de réponse
22 nov. 2022 11h45 HE
|
Eurobio Scientific
Eurobio Scientific et Acobiom annoncent la signature d’un accord commercial pour la distribution exclusive d’un test diagnostique prédictif de réponseà un traitement du cancer du pancréas Test...
EUROBIO : MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2022
27 oct. 2022 12h00 HE
|
Eurobio Scientific
MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2022 Paris, le 27 octobre 2022 – 18h00 Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic...
EUROBIO SCIENTIFIC: H1 2022 RESULTS CONTINUED GROWTH OF NON-COVID ACTIVITY
11 oct. 2022 02h00 HE
|
Eurobio Scientific
H1 2022 RESULTS CONTINUED GROWTH OF NON-COVID ACTIVITY • Decisive and strategic move with the acquisitions of GenDx and bmd Belgium• Non-COVID activity increases by...
EUROBIO SCIENTIFIC : RESULTATS S1 2022 CROISSANCE CONTINUE DE L’ACTIVITE HORS COVID
11 oct. 2022 02h00 HE
|
Eurobio Scientific
RESULTATS S1 2022 CROISSANCE CONTINUE DE L’ACTIVITE HORS COVID Avancée stratégique décisive avec les acquisitions de GenDX et bmd BelgiqueActivité hors Covid en augmentation de +5,1 % EBITDA de +26...
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST
03 oct. 2022 11h50 HE
|
Eurobio Scientific
EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST • Acceleration of strategic plan confirming its positioning as a leader in the molecular...
EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DE GENDX, SPECIALISTE INTERNATIONAL DU DIAGNOSTIC HLA
03 oct. 2022 11h50 HE
|
Eurobio Scientific
EUROBIO SCIENTIFIC FINALISE L’ACQUISITION DE GENDX, SPECIALISTE INTERNATIONAL DU DIAGNOSTIC HLA Accélération du plan stratégique confirmant le positionnement d’Eurobio Scientific en tant que leader...
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST
17 août 2022 12h00 HE
|
Eurobio Scientific
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST • Acceleration of strategic plan confirming its positioning as a leader in the molecular...